We Claim,

1. A recombinant lectin for use in a method of treatment of cancer by inhibiting angiogenesis in a subject comprising administration of a therapeutically effective amount of the recombinant lectin.
2. A recombinant lectin for use in a method of treatment of cancer by inducing apoptosis in subject comprising administration of a therapeutically effective amount of the recombinant lectin.
3. The recombinant lectin as claimed in claim 1 and 2, wherein said cancer is carcinoma.
4. The recombinant lectin as claimed in claim 3, wherein said cancer is adenocarcinoma or squamous cell carcinoma.
5. The recombinant lectin as claimed in claim 4, wherein adenocarcinoma is selected from oesophageal, pancreatic, prostate, cervical, breast, colon or colorectal, lung, bile duct, vaginal, urachus or stomach adenocarcinoma.
6. The recombinant lectin as claimed in claim 4, wherein squamous cell carcinoma skin, lung, oral, thyroid, oesophagus, vaginal, cervical, ovarian, head and/or neck, prostate or bladder squamous cell carcinoma
7. The recombinant lectin as claimed in claim 3, wherein the cancer is brain cancer.
8. The recombinant lectin as claimed in any one of the preceding claims, wherein the recombinant lectin is represented by an amino acid sequence having at least 60% identity to SEQ ID NO. 1.
9. The recombinant lectin as claimed in claim 8, wherein the amino acid sequence has at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% homology to SEQ ID NO. 1.

10. The recombinant lectin as claimed in claim 8 and 9, wherein the amino acid sequence is selected from SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4.

11. The recombinant lectin as claimed in claim 1 to 10, wherein the effective concentration of recombinant lectin is from 0.1 μg/mL to about 200 μg/mL.

12. The recombinant lectin as claimed in claim 1 to 10, wherein the therapeutically effective dose of recombinant lectin is from 0.1 mg/Kg to 100 mg/Kg body weight of a subject.

13. The recombinant lectin as claimed in any one of the preceding claims, wherein the lectin inhibits migration and/or proliferation of endothelial cells.

14. The recombinant lectin as claimed in any one of the preceding claims, wherein the lectin modulates VEGF secretion.

15. The recombinant lectin as claimed in any one of the preceding claims, wherein the lectin reduces hemoglobin content and neovascularization in cancer cells.

16. The recombinant lectin as claimed in any one of the preceding claims, wherein the lectin modulates one or more signaling pathways selected from: ATF-2, ERK1/2; JNK; MEK-1; P90RSK; STAT-3; p53; MMPs; HGF; C-kit;; Her-2; GMSCF; IL-6; IL-8; p38/MAPK; PDGF; TNFR; MPO; Galectin-3; Fol-1; CD40L; Angiopoietin-2; Kalikrein-5; Osteopontin; TNF-α; Endoglin; CCR5; TRAIL *via* FADD and caspase – 3, Leptin; MAPK/EGFR/Ras/Raf; ADBR1; IL-4/STAT6; NF-KB; TNF-α/JNK, PKC/CA2+; and PI3K/AKT/FOXO3.

17. The recombinant lectin as claimed in claim 2, wherein the lectin induces early and late stage of apoptosis in the cancer cells.

18. A method of preventing angiogenesis in cancer cells using a recombinant lectin protein.

19. A method of inducing apoptosis of tumor cells using a recombinant lectin protein.

20. A method of treatment of cancer by inhibiting angiogenesis in the cancer cells, wherein the method comprises administration of therapeutically effective amount of recombinant lectin to a subject.

21. A method of treatment of cancer by inducing apoptosis in the cancer cells, wherein the method comprises administration of therapeutically effective amount of recombinant lectin to a subject.

22. A pharmaceutical composition for use in the method of treatment of cancer comprising a recombinant lectin protein and a pharmaceutically acceptable excipient, wherein the composition inhibits angiogenesis in the cancer cells.

23. A pharmaceutical composition for use in the method of treatment of cancer comprising a recombinant lectin protein and a pharmaceutically acceptable excipient, wherein the composition induces apoptosis in the cancer cells.

24. The method of treatment as claimed in claim 19 or 20 wherein the method comprises administration of lectin as claimed in claim 1 to 16.

25. The composition as claimed in claim 21 or 22 wherein the composition comprises lectin as claimed in claim 1 to 16.

26. A recombinant lectin for use in a method of treatment of pancreatic cancer, cervical cancer, breast cancer, colon or colorectal cancer, bladder cancer, ovary cancer or brain cancer, comprising administration of a therapeutically effective amount of the recombinant lectin.